Home
PAVM
PAVM News

Latest PAVmed Inc. (PAVM) News on September 7, 2025

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

PR Newswire

25 days ago

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

PR Newswire

2 months ago

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

PR Newswire

3 months ago

Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

PAVmed subsidiary Veris Health partners with Ohio State University cancer center

TipRanks

3 months ago

PAVmed subsidiary Veris Health partners with Ohio State University cancer center

MT Newswires

3 months ago

Pavmed's Veris Health Signs Long-Term Partnership Deal With Ohio State University Hospital

PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

PR Newswire

3 months ago

PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

PR Newswire

3 months ago

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

PAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial Fortification

GuruFocus.com

4 months ago

PAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial Fortification

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

PR Newswire

4 months ago

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

PR Newswire

4 months ago

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

PR Newswire

4 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

PR Newswire

4 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know

Zacks

4 months ago

PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

PR Newswire

4 months ago

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

PR Newswire

5 months ago

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

PR Newswire

5 months ago

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

PR Newswire

5 months ago

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

PR Newswire

5 months ago

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

PR Newswire

5 months ago

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Growth and Financial Stability

GuruFocus.com

5 months ago

PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Growth and Financial Stability

Thomson Reuters StreetEvents

5 months ago

Q4 2024 PAVmed Inc Earnings Call

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

PR Newswire

5 months ago

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

PR Newswire

5 months ago

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

PR Newswire

6 months ago

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

PR Newswire

6 months ago

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

PR Newswire

6 months ago

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025

PR Newswire

6 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

PR Newswire

6 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

PR Newswire

6 months ago

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

MT Newswires

6 months ago

Lucid Diagnostics Prices $15.3 Million Direct Offering

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

PR Newswire

6 months ago

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

PR Newswire

6 months ago

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PR Newswire

6 months ago

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PAVmed and Subsidiary Veris Health Complete Private Placement Financing

PR Newswire

6 months ago

PAVmed and Subsidiary Veris Health Complete Private Placement Financing

Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health

PR Newswire

7 months ago

Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health

MT Newswires

7 months ago

PAVmed Regains Compliance With Nasdaq Listing Standards

PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement

PR Newswire

7 months ago

PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement

Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

PR Newswire

7 months ago

Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

PR Newswire

8 months ago

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

PR Newswire

8 months ago

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

PR Newswire

9 months ago

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

PR Newswire

9 months ago

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

PR Newswire

9 months ago

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

PR Newswire

10 months ago

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

PR Newswire

10 months ago

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

PAVmed Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

10 months ago

PAVmed Third Quarter 2024 Earnings: Misses Expectations

Thomson Reuters StreetEvents

10 months ago

Q3 2024 PAVmed Inc Earnings Call

PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring

GuruFocus.com

10 months ago

PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring

PAVmed Provides Business Update and Third Quarter 2024 Financial Results

PR Newswire

10 months ago

PAVmed Provides Business Update and Third Quarter 2024 Financial Results

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

PR Newswire

10 months ago

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

PR Newswire

10 months ago

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024

PR Newswire

10 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

PR Newswire

10 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test

PR Newswire

a year ago

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test

PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care

PR Newswire

a year ago

PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

PR Newswire

a year ago

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024

PR Newswire

a year ago

Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024

Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players

PR Newswire

a year ago

Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players

American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test

PR Newswire

a year ago

American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test

PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

PR Newswire

a year ago

PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress

PR Newswire

a year ago

Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress

Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health

PR Newswire

a year ago

Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health

Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer

PR Newswire

a year ago

Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer

PAVmed Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

a year ago

PAVmed Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Thomson Reuters StreetEvents

a year ago

Q2 2024 PAVmed Inc Earnings Call

The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer

PR Newswire

a year ago

The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer

PAVmed Provides Business Update and Second Quarter 2024 Financial Results

PR Newswire

a year ago

PAVmed Provides Business Update and Second Quarter 2024 Financial Results

Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results

PR Newswire

a year ago

Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results

Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event

PR Newswire

a year ago

Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event

Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing

PR Newswire

a year ago

Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing

Lucid Diagnostics to Participate in Upcoming Investor Conferences

PR Newswire

a year ago

Lucid Diagnostics to Participate in Upcoming Investor Conferences

PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024

PR Newswire

a year ago

PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024

PR Newswire

a year ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

PR Newswire

a year ago

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

Lucid Diagnostics Launches New Corporate Website

PR Newswire

a year ago

Lucid Diagnostics Launches New Corporate Website

Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

PR Newswire

a year ago

Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

PR Newswire

a year ago

PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing

PR Newswire

a year ago

4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing

Italian energy company targets Britain for fleet of 20 mini-nukes

The Telegraph

a year ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Simply Wall St.

a year ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

Simply Wall St.

a year ago

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Motley Fool

a year ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Simply Wall St.

a year ago

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

Simply Wall St.

a year ago

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

Seoul resumes loudspeaker propaganda against North

AFP

a year ago

Seoul resumes loudspeaker propaganda against North

Lotto 6/49 - $64 million up for grabs in the next draw!

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

GuruFocus.com

a year ago

PAVmed Inc (PAVM) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ...

Thomson Reuters StreetEvents

a year ago

Q1 2024 PAVmed Inc Earnings Call

PAVmed Provides Business Update and First Quarter 2024 Financial Results

PR Newswire

a year ago

PAVmed Provides Business Update and First Quarter 2024 Financial Results

Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results

PR Newswire

a year ago

Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

PR Newswire

a year ago

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

PR Newswire

a year ago

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

Share on Social Networks: